PDGFB Rearrangement

CI-VAR-00003968Explore in graph →CIViC 4003

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Dermatofibrosarcoma Protuberans3
PDGFB Rearrangement	Imatinib Mesylate	Predictive	C	Supports Sensitivity Response	3	submitted	EID10312 An 18-month-old female patient presented with a history of an enlarging, subcutaneous mass in her right lower extremity since birth. A biopsy was performed and the findings were typical of Dermatofibr… (full text at CIViC) PMID 15503291 · Price et al., 2005 · Open in CIViC	civic
PDGFB Rearrangement	Imatinib Mesylate	Predictive	C	Supports Sensitivity Response	2	submitted	EID10330 In this retrospective study, two patients with locally advanced Dermatofibrosarcoma Protuberans (DFSP) and two patients with recurrent DFSP received imatinib treatment prior to undergoing Mohs surgery… (full text at CIViC) PMID 19620561 · Han et al., 2009 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.